ArticleBMC oral health2026
Impact of selective serotonin reuptake inhibitors on major salivary glands and mandibular alveolar bone; a histological, histochemical and biochemical study.
Article in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSelective serotonin reuptake inhibitors (SSRIs) are a novel type of antidepressant (AD) that can be used as a first-line treatment for depression and other mental illnesses. Long-term AD use is becoming more frequent, with many people continuing to get therapy for extended periods of time. This surge has been linked to a number of health concerns, including an increased risk of fractures, lower bone mineral density in young adults, and a significantly elevated risk of dry mouth, all of which can have a negative impact on dental health and general quality of life. This study aimed to evaluate the effect of Cipralex (SSRI) on the histological structure of major salivary glands and alveolar bone, as well as its impact on pro-inflammatory cytokines interleukin 1 beta (IL-1β) and Tumor necrosis factor alpha (TNF-α).
methods18 rats were randomly separated into two groups (n = 9 each): a control group and a Cipralex-treated group receiving 10 mg/kg/day orally by gavage for four weeks. Major salivary glands and mandibular molar region specimens were collected for histological evaluation using hematoxylin and eosin( H&E) staining. Alveolar bone specimens were stained with Masson’s trichrome (MT), and histomorphometric analysis of newly formed collagen area percentage was performed using ImageJ software. Serum IL-1β and TNF-α levels were quantified using enzyme-linked immunosorbent assay (ELISA).
resultsThe Cipralex group’s histological analysis showed that the architecture of the normal major SGs had deteriorated notably, and there were indications of bone resorption in the alveolar bone. There was a statistically significant decrease in the amount of newly produced collagen compared with controls (p < .05). Biochemical analysis showed a significant decrease in serum IL-1β levels in the Cipralex group (245.22 ± 5.04) versus control (262.67 ± 4.88), while TNF-α levels did not differ significantly between groups ( control ; 693.88 ± 8.65, cipralex; 695.84 ± 7.06) p = .607 .
conclusionsLong-term use of Cipralex may compromise the integrity of the salivary glands and raise the possibility of alveolar bone resorption. These results highlight the significance of dental and periodontal monitoring in patients undergoing long-term antidepressant treatment and emphasize possible oral health problems linked to long-term SSRI therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.